Increased Uptake of the Apoptosis-imaging Agent 99mTc Recombinant Human Annexin V in Human Tumors after One Course of Chemotherapy as a Predictor of Tumor Response and Patient Prognosis Export

@article{citeulike:1182695, abstract = {Purpose: Many anticancer therapies exert their therapeutic effect by inducing apoptosis in target tumors. We evaluated in a Phase I study the safety and the feasibility of 99mTc-Annexin V for imaging chemotherapy-induced apoptosis in human cancers immediately after the first course of chemotherapy. Experimental Design: Fifteen patients presenting with lung cancer (n = 10), lymphoma (n = 3), or breast cancer (n = 2) underwent 99mTc-Annexin V scintigraphy before and within 3 days after their first course of chemotherapy. Tumor response was evaluated by computed tomography and 18F-fluoro-2-deoxy-D-glucose positron emission tomography scans, 3 months in average after completing the treatment. Median follow-up was 117 days. Results: In all cases, no tracer uptake was observed before treatment. However, 24-48 h after the first course of chemotherapy, 7 patients who showed 99mTc-Annexin V uptake at tumor sites, suggesting apoptosis, had a complete (n = 4) or a partial response (n = 3). Conversely, 6 of the 8 patients who showed no significant posttreatment tumor uptake had a progressive disease. Despite the lack of tracer uptake after treatment, the 2 patients with breast cancer had a partial response. Overall survival and progression-free survival were significantly related to tracer uptake in treated lung cancers and lymphomas (P < 0.05). No serious adverse events were observed. Conclusions: Our preliminary results demonstrated the feasibility and the safety of 99mTc-Annexin V for imaging apoptosis in human tumors after the first course of chemotherapy. Initial data suggest that early 99mTc-Annexin V tumor uptake may be a predictor of response to treatment in-patients with late stage lung cancer and lymphoma.}, author = {Belhocine, Tarik and Steinmetz, Neil and Hustinx, Roland and Bartsch, Pierre and Jerusalem, Guy and Seidel, Laurence and Rigo, Pierre and Green, Allan}, citeulike-article-id = {1182695}, citeulike-linkout-0 = {http://clincancerres.aacrjournals.org/cgi/content/abstract/8/9/2766}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/12231515}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=12231515}, day = {1}, journal = {Clin Cancer Res}, keywords = {annexin-v, apoptosis, paper1, pet, treatment-response}, month = {September}, number = {9}, pages = {2766--2774}, posted-at = {2007-03-24 13:39:34}, priority = {2}, title = {Increased Uptake of the Apoptosis-imaging Agent 99mTc Recombinant Human Annexin V in Human Tumors after One Course of Chemotherapy as a Predictor of Tumor Response and Patient Prognosis}, url = {http://clincancerres.aacrjournals.org/cgi/content/abstract/8/9/2766}, volume = {8}, year = {2002} }

TY - JOUR ID - citeulike:1182695 L3 - citeulike-article-id:1182695 N2 - Purpose: Many anticancer therapies exert their therapeutic effect by inducing apoptosis in target tumors. We evaluated in a Phase I study the safety and the feasibility of 99mTc-Annexin V for imaging chemotherapy-induced apoptosis in human cancers immediately after the first course of chemotherapy. Experimental Design: Fifteen patients presenting with lung cancer (n = 10), lymphoma (n = 3), or breast cancer (n = 2) underwent 99mTc-Annexin V scintigraphy before and within 3 days after their first course of chemotherapy. Tumor response was evaluated by computed tomography and 18F-fluoro-2-deoxy-D-glucose positron emission tomography scans, 3 months in average after completing the treatment. Median follow-up was 117 days. Results: In all cases, no tracer uptake was observed before treatment. However, 24-48 h after the first course of chemotherapy, 7 patients who showed 99mTc-Annexin V uptake at tumor sites, suggesting apoptosis, had a complete (n = 4) or a partial response (n = 3). Conversely, 6 of the 8 patients who showed no significant posttreatment tumor uptake had a progressive disease. Despite the lack of tracer uptake after treatment, the 2 patients with breast cancer had a partial response. Overall survival and progression-free survival were significantly related to tracer uptake in treated lung cancers and lymphomas (P < 0.05). No serious adverse events were observed. Conclusions: Our preliminary results demonstrated the feasibility and the safety of 99mTc-Annexin V for imaging apoptosis in human tumors after the first course of chemotherapy. Initial data suggest that early 99mTc-Annexin V tumor uptake may be a predictor of response to treatment in-patients with late stage lung cancer and lymphoma. IS - 9 JF - Clin Cancer Res EP - 2774 TI - Increased Uptake of the Apoptosis-imaging Agent 99mTc Recombinant Human Annexin V in Human Tumors after One Course of Chemotherapy as a Predictor of Tumor Response and Patient Prognosis VL - 8 SP - 2766 KW - annexin-v KW - apoptosis KW - paper1 KW - pet KW - treatment-response AU - Belhocine, Tarik AU - Steinmetz, Neil AU - Hustinx, Roland AU - Bartsch, Pierre AU - Jerusalem, Guy AU - Seidel, Laurence AU - Rigo, Pierre AU - Green, Allan PY - 2002/09/01/ UR - http://clincancerres.aacrjournals.org/cgi/content/abstract/8/9/2766 ER -